EyePoint Pharmaceuticals announced that the company’s permanent and specific J-Code for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the Centers for Medicare and Medicaid Services (CMS) one quarter earlier than under prior CMS policy.
“Uveitis specialists, insurers and patients now stand to benefit from a more streamlined, efficient and permanent reimbursement process with the addition of our new Yutiq-specific J-Code,” Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals, said in a company news release. “This milestone is particularly important as J-Codes are utilized by CMS and commercial insurers, and the early issuance allows for our best-in-class approval and reimbursement process to be in effect sooner than we had previously anticipated. Since our Yutiq commercial launch in February, we continue to receive strong reception from treating physicians and the greater medical community on Yutiq’s clinical and long-duration treatment profile.”